Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
SAN FRANCISCO, Sept. 26, 2017 -- Hagens Berman Sobol Shapiro LLP reminds investors in Electronics For Imaging, Inc. (NASDAQ:EFII) of the October 10, 2017 Lead Plaintiff deadline in the pending securities class action.
If you purchased or otherwise acquired securities of EFII between February 22, 2017 and August 3, 2017 and suffered losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/EFII
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing
On August 3, 2017, EFII announced in a press release filed with the U.S. Securities and Exchange Commission that it delayed its second quarter 2017 earnings conference call because it was still assessing certain revenue recognition issues involving product stored at a third party in-transit warehouse before delivery to the end user.
This news drove the price of EFII shares down $21.61, or approximately 45%, to close at $26.05 on August 4, 2017.
On September 11, 2017, EFII filed its amended annual report for the year ended December 31, 2016 with the SEC announcing management determined the Company lacked sufficient internal controls over financial reporting and its auditor expressed an adverse opinion about the sufficiency of those controls. The Company maintained no financial restatements were necessary.
“We’re focused on when EFII management first became aware of the Company’s control weaknesses and damages investors suffered when management admitted to the material weaknesses,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding EFII should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with 11 offices across the country. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact:
Reed Kathrein, 510-725-3000
